We are excited to be a financing partner to the most talented entrepreneurs in Switzerland. Our entrepreneurs are pioneers who are redefining or creating new market segments :
Based on a concept validated at CERN, Transmutex aims to couple a particle accelerator to a thorium fission reactor with the goal of efficiently reducing the stockpile of existing nuclear waste while producing carbon-free energy.
Haya Therapeutics is developing long non-coding RNAs to target fibrosis in the heart. This unique approach is being developed to treat heart failure and also offers potential to target fibrosis in other organs